GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » Operating Income

IRD (Opus Genetics) Operating Income : $-34.07 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Operating Income?

Opus Genetics's Operating Income for the three months ended in Dec. 2024 was $-10.03 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-34.07 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Opus Genetics's Operating Income for the three months ended in Dec. 2024 was $-10.03 Mil. Opus Genetics's Revenue for the three months ended in Dec. 2024 was $4.30 Mil. Therefore, Opus Genetics's Operating Margin % for the quarter that ended in Dec. 2024 was -233.12%.

Opus Genetics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Opus Genetics's annualized ROC % for the quarter that ended in Dec. 2024 was -24,460.98%. Opus Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -111,539.68%.


Opus Genetics Operating Income Historical Data

The historical data trend for Opus Genetics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Operating Income Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Income
Get a 7-Day Free Trial -9.47 -22.71 18.23 -10.56 -34.07

Opus Genetics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.43 -7.71 -8.33 -8.01 -10.03

Opus Genetics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opus Genetics  (NAS:IRD) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Opus Genetics's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-40.116 * ( 1 - 0% )/( (0.073999999999998 + 0.254)/ 2 )
=-40.116/0.164
=-24,460.98 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=40.389 - 6.015 - ( 36.635 - max(0, 6.089 - 40.389+36.635))
=0.073999999999998

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Opus Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-140.54/( ( (0 + max(-3.803, 0)) + (0.252 + max(-7.217, 0)) )/ 2 )
=-140.54/( ( 0 + 0.252 )/ 2 )
=-140.54/0.126
=-111,539.68 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.857 + 0 + 0.429) - (6.015 + 0 + 0.074000000000001)
=-3.803

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.563 + 0 + 0.515) - (11.293 + 0 + 0.0020000000000007)
=-7.217

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Opus Genetics's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-10.029/4.302
=-233.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Opus Genetics Operating Income Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Opus Genetics Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Executives
George Magrath officer: Chief Executive Officer 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel officer: SVP, Operations & Bus. Dev. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch director, officer: President and CEO 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J director 5130 ROUTE 212, WILLOW NY 12495
Jay Pepose director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton director 3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba officer: VP of Finance 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer director
Sean Ainsworth director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann officer: VP of Corp. Dev. & Ops & Sec. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price director 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky officer: President and CFO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732